What are the guidelines for treatment of multiple sclerosis (MS) with an FDA-approved disease-modifying agent?

Updated: Oct 08, 2019
  • Author: Christopher Luzzio, MD; Chief Editor: Jasvinder Chawla, MD, MBA  more...
  • Print

Currently, most disease-modifying agents have been approved for use only in relapsing forms of MS. To address the need for early intervention, the Multiple Sclerosis Coalition developed a consensus document in 2014 to provide support for broader access to U.S. Food and Drug Administration (FDA)-approved MS disease-modifying therapies. [142]  

The guidelines recommend treatment with an FDA-approved disease-modifying agent as soon as possible after any of the following events:

  • Diagnosis of relapsing MS
  • First episode of neurologic symptoms with MRI findings consistent with MS, and other possible causes have been ruled out
  • Diagnosis of secondary-progressive MS (SPMS) but patient continues to have relapses and/or inflammatory changes on MRI

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!